Phase 3 hypothalamic obesity top-line data expected in 1H2025 Positive reimbursement decision achieved for IMCIVREE® to treat patients with Bardet-Biedl syndrome and POMC/LEPR.
LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation Rhythm to advance LB54640 in two Phase 2 clinical trials BOSTON, Jan. 04, 2024 Rhythm Pharmaceuticals,.
Rhythm Pharmaceuticals Announces New Employment Inducement Grants menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases Approximately 150 healthcare professionals.